TRA2A Binds With LncRNA MALAT1 To Promote Esophageal Cancer Progression By Regulating EZH2/β-catenin Pathway

Area of Science:

• Molecular Biology
• Oncology
• RNA Biology

Background:

• The RNA binding protein TRA2A (Transformer 2 homolog A) is known for its role in pre-mRNA alternative splicing.
• Its involvement in non-coding RNA regulation and functional consequences in cancer remain largely unexplored.
• Esophageal cancer is a significant global health concern with complex molecular underpinnings.

Purpose of the Study:

• To investigate the role of TRA2A in esophageal cancer.
• To determine if TRA2A regulates non-coding RNAs, specifically MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1).
• To elucidate the functional consequences of TRA2A-MALAT1 interaction in esophageal carcinogenesis.

Main Methods:

• Analysis of expression profiling data to correlate TRA2A expression with esophageal cancer survival.
• Gain- and loss-of-function studies to assess TRA2A's impact on cancer cell proliferation and migration.
• RNA immunoprecipitation and RNA pull-down assays to confirm direct binding of TRA2A to MALAT1.
• Investigation of the EZH2/β-catenin signaling pathway modulation by TRA2A and MALAT1.

Main Results:

• TRA2A is highly expressed in esophageal cancer and associated with poorer disease-free and overall survival.
• TRA2A promotes proliferation and migration in esophageal squamous cell carcinoma and adenocarcinoma cells.
• TRA2A directly binds to MALAT1, and its expression levels correlate with MALAT1 expression.
• TRA2A modulates the EZH2/β-catenin pathway through MALAT1 regulation.

Conclusions:

• TRA2A acts as an oncogene in esophageal cancer by promoting cell proliferation and migration.
• TRA2A regulates the long non-coding RNA MALAT1, which in turn influences the EZH2/β-catenin signaling axis.
• The TRA2A-MALAT1-EZH2/β-catenin axis represents a novel mechanism driving esophageal carcinogenesis.